Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector

被引:15
作者
Almeida, Juliana F. [1 ,2 ]
Breyner, Natalia M. [1 ,2 ]
Mahi, Miloud [1 ,3 ]
Ahmed, Bensoltane [3 ]
Benbouziane, Bouasria [1 ,4 ]
Boas, Priscilla C. B. Vilas [1 ,2 ]
Miyoshi, Anderson [2 ]
Azevedo, Vasco [2 ]
Langella, Philippe [1 ]
Bermudez-Humaran, Luis G. [1 ]
Chatel, Jean-Marc [1 ]
机构
[1] Univ Paris Saclay, AgroParisTech, INRA, Micalis Inst, F-78350 Jouy En Josas, France
[2] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
[3] Univ Nat Life & Hearth Sci, Food Microbiol Lab, Dept Biol, Theniat El Had St, Khemis Miliana 44225, Algeria
[4] Univ Mostaganem, Dept Biol, Lab Beneficial Microorganisms Funct Foods & Hlth, Lahcen St,POB 300, Mostaganem 27000, Algeria
关键词
Lactic acid bacteria; Protein vaccination; Fibronectin binding protein A (FnBPA); Human papillomavirus (HPV); HPV-16-E7; antigen; EPITHELIAL-CELLS; DENDRITIC CELLS; ACID BACTERIA; TYPE-16; E7; IN-VIVO; MONOCYTOGENES INTERNALIN; MUCOSAL DELIVERY; IMMUNIZATION; ANTIGEN; DNA;
D O I
10.1016/j.vaccine.2016.01.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A recombinant strain of Lactococcus lactis displaying a cell-surface anchored fibronectin binding protein A (FnBPA) from Staphylococcus aureus (LL-FnBPA) had been shown to be more efficient in delivering plasmid than its wild-type counterpart both in vitro and in vivo, and have the ability to orientate the immune response toward a Th2 profile in a context of a DNA vaccination. The aim of this work was to test whether this LL-FnBPA strain could shape the immune response after mucosal administration in mice. For this, we used a mouse model of human papilloma virus (HPV)-induced cancer and a L. lactis strain displaying at its cell surface both HPV-16-E7 antigen (LL-E7) and FnBPA (LL-E7 + FnBPA). Our results revealed a more efficient systemic Th1 immune response with recombinant LL-E7 + FnBPA. Furthermore, mice vaccinated with LL-E7 + FnBPA were better protected when challenged with HPV-16-induced tumors. Altogether, the results suggest that FnBPA displays adjuvant properties when used in the context of mucosal delivery using L. lactis as a live vector. (C) 2016 Published by Elsevier Ltd.
引用
收藏
页码:1312 / 1318
页数:7
相关论文
共 32 条
  • [1] Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7
    Adachi, Katsuyuki
    Kawana, Kei
    Yokoyama, Terufumi
    Fujii, Tomoyuki
    Tomio, Ayako
    Miura, Shiho
    Tomio, Kensuke
    Kojima, Satoko
    Oda, Katsutoshi
    Sewaki, Tomomitsu
    Yasugi, Toshiharu
    Kozuma, Shiro
    Taketani, Yuji
    [J]. VACCINE, 2010, 28 (16) : 2810 - 2817
  • [2] Correlation between fibronectin binding protein A expression level at the surface of recombinant lactococcus lactis and plasmid transfer in vitro and in vivo
    Almeida, Juliana F.
    Mariat, Denis
    Azevedo, Vasco
    Miyoshi, Anderson
    de Moreno de LeBlanc, Alejandra
    del Carmen, Silvina
    Martin, Rebeca
    Langella, Philippe
    LeBlanc, Jean-Guy
    Chatel, Jean-Marc
    [J]. BMC MICROBIOLOGY, 2014, 14
  • [3] A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors
    Bermúdez-Humarán, LG
    Cortes-Perez, NG
    Lefèvre, F
    Guimaraes, V
    Rabot, S
    Alcocer-Gonzalez, JM
    Gratadoux, JJ
    Rodriguez-Padilla, C
    Tamez-Guerra, RS
    Corthier, G
    Gruss, A
    Langella, P
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (11) : 7297 - 7302
  • [4] An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci
    Bermúdez-Humarán, LG
    Cortes-Perez, NG
    Le Loir, Y
    Alcocer-González, JM
    Tamez-Guerra, RS
    de Oca-Luna, RM
    Langella, P
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (05) : 427 - 433
  • [5] Fusion to a carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in Lactococcus lactis
    Bermúdez-Humarán, LG
    Cortes-Perez, NG
    Le Loir, Y
    Gruss, A
    Rodriguez-Padilla, C
    Saucedo-Cardenas, O
    Langella, P
    de Oca-Luna, RM
    [J]. BIOTECHNOLOGY PROGRESS, 2003, 19 (03) : 1101 - 1104
  • [6] Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production
    Bermúdez-Humarán, LG
    Langella, P
    Cortes-Perez, NG
    Gruss, A
    Tamez-Guerra, RS
    Oliveira, SC
    Saucedo-Cardenas, O
    de Oca-Luna, RM
    Le Loir, Y
    [J]. INFECTION AND IMMUNITY, 2003, 71 (04) : 1887 - 1896
  • [7] Production of human papillomavirus type 16 E7 protein in Lactococcus lactis
    Bermúdez-Humarán, LG
    Langella, P
    Miyoshi, A
    Gruss, A
    Guerra, RT
    de Oca-Luna, RM
    Le Loir, Y
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (02) : 917 - 922
  • [8] Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins
    Bermudez-Humaran, Luis G.
    [J]. HUMAN VACCINES, 2009, 5 (04): : 264 - 267
  • [9] In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells
    Chatel, J-M
    Pothelune, L.
    Ah-Leung, S.
    Corthier, G.
    Wal, J-M
    Langella, P.
    [J]. GENE THERAPY, 2008, 15 (16) : 1184 - 1190
  • [10] Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria
    Cortes-Perez, Naima G.
    Lefevre, Francois
    Corthier, Gerard
    Adel-Patient, Karine
    Langella, Philippe
    Bermudez-Humaran, Luis G.
    [J]. VACCINE, 2007, 25 (36) : 6581 - 6588